GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment ConferenceBusiness Wire • 09/07/22
GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022Business Wire • 08/03/22
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare ConferenceBusiness Wire • 06/02/22
GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/30/22
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022Business Wire • 04/28/22
GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/03/22
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2021Business Wire • 03/03/22
GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical OperationsBusiness Wire • 03/02/22
GlycoMimetics to Report Fourth Quarter and 2021 Year-End Financial Results on March 3, 2022Business Wire • 02/25/22
GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial OfficerBusiness Wire • 02/23/22
Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and E-selectinBusiness Wire • 12/13/21
NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of ScheduleBusiness Wire • 12/06/21
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatment of AMLBusiness Wire • 11/23/21
GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory AffairsBusiness Wire • 11/22/21
GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)Business Wire • 11/15/21